ProfileGDS5678 / 1448562_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 90% 89% 86% 90% 82% 78% 82% 80% 89% 92% 91% 91% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9358689
GSM967853U87-EV human glioblastoma xenograft - Control 27.2686590
GSM967854U87-EV human glioblastoma xenograft - Control 37.0478689
GSM967855U87-EV human glioblastoma xenograft - Control 46.7299286
GSM967856U87-EV human glioblastoma xenograft - Control 57.3700890
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7754682
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2627378
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9240182
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6850480
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1280389
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.5480692
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.4435691
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.4592991
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.6461792